Differences between the United States and Japan in labels of oncological drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Differences between the United States and Japan in labels of oncological drugs

Published:2016-09-26 Issue:2 Volume:26 Page:143-151
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Jayaputra Karina¹,Ono Shunsuke¹

Affiliation:

1. Laboratory of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences; The University of Tokyo; Tokyo Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference33 articles.

1. Contraindication labelling changes in the United States and Germany;Garbe;Eur Journal Clin Pharmacol,2007

2. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan;Shimazawa;J Clin Pharm Ther,2013

3. Assessment of factors associated with dose differences between Japan and the United States;Arnold;Clin Pharmacol Ther,2014

4. Safety information in drug labeling: a comparison of the USA, the UK, and Japan;Shimazawa;Pharmacoepidemiol Drug Saf,2013

5. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan;Saito;J Clin Pharm Ther,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Provision and Need for Medicine Information in Asia and Africa: A Scoping Review of the Literature;Drug Safety;2021-03-05

2. Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels;Regulatory Toxicology and Pharmacology;2018-10

3. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans;Pharmacoepidemiology and Drug Safety;2018-09-05

4. Analysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks;Pharmaceutical Medicine;2017-07-13

5. Oncological drug labelling: Japan vs USA;Reactions Weekly;2016-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3